September 23, 2017

September 22, 2017

Subscribe to Latest Legal News and Analysis

September 21, 2017

Subscribe to Latest Legal News and Analysis

September 20, 2017

Subscribe to Latest Legal News and Analysis

CMS Notifies States of AMP Rule Requirements: 340B Providers Should Take Note

Last week, we wrote analyzing key provisions of the Covered Outpatient Drug final rule (“Final AMP Rule”) and their impact on manufacturers, pharmacy benefit managers (“PBMs”), and pharmacies.  We focused on the following four provisions: (i) the definition of bona fide service fees; (ii) the definition of bundled sales; (iii) the definition of retail community pharmacy; and (iv) the change in Medicaid reimbursement to reimbursement based on Actual Acquisition Cost (“AAC”).

On the heels of the release of the Final AMP Rule, CMS released a State Medicaid Director Letter providing guidance on implementation of the Final AMP Rule.  The letter provides practical instructions to the states on their obligation to adopt a Medicaid reimbursement methodology for AAC that reflects the “actual prices” pharmacy providers paid to acquire the drugs.  In addition to instructions for setting a Medicaid reimbursement methodology based on AAC, the letter advises states on their obligation to set a professional dispensing fee that reflects the pharmacist’s professional services and costs. CMS does not dictate that states use a specific methodology or formula for establishing a professional dispensing fee, but warns that the fee must be sufficient to provide adequate reimbursement and ensure sufficient beneficiary access.

In the State Medicaid Director Letter, CMS also instructs states that their obligation to reimburse pharmacies at AAC carries consequences for the 340B Drug Discount Program. The AAC-based Medicaid reimbursement for drugs purchased through the 340B program should not exceed the 340B ceiling price – the price at which most covered entities will purchase the drug.  The requirement to reimburse at no more than the 340B ceiling price will apply regardless of whether the reimbursement is made to a 340B covered entity or its contract pharmacy.

A handful of states, such as California, already have approved State Plan Amendments (“SPA”) where reimbursement is the lesser of AAC or the 340B ceiling price.  In the states that already use AAC for 340B, 340B providers or their contract pharmacies are generally required to bill Medicaid using the actual acquisition cost of the drug, which is often the ceiling price, and are required to use a modifier on the claim that notifies the state that the drug should be exempt from Medicaid Drug Rebate invoicing.  But this requirement is not uniform.  Under the AMP Rule, all states will be required to ensure their SPA reflects an AAC or ceiling price-based payment methodology for 340B entities.

It is interesting to note that CMS specified that AAC or ceiling price reimbursement extends to 340B contract pharmacies.  Several states not only currently use AAC or 340B ceiling price as the Medicaid reimbursement rate, they also prohibit 340B covered entities or their contract pharmacies from excluding Medicaid patients from receiving 340B drugs; those states want to ensure Medicaid gets to share in the savings from 340B.  However, as we blogged in the past, this is slightly at odds with HRSA’s proposed 340B Drug Pricing Program Omnibus Guidance (“Proposed Guidance”), in which HRSA recommended that contract pharmacies default to excluding Medicaid  patients.  HRSA stated that “it will be presumed that the contract pharmacy will not dispense 340B drugs for its Medicaid fee-for-service (“FFS”) or MCO patients.”  The contract pharmacy can dispense 340B drugs to Medicaid patients only if the covered entity “wishes” to make those drugs available to Medicaid members and provides HRSA with a written agreement describing compliant procedures.

The 340B provisions in the Final AMP Rule and subsequent CMS instructions will require State Medicaid programs to re-evaluate and update their 340B payment methodology.  In doing so, states may place additional requirements on 340B covered entities and 340B contract pharmacies – such as requirements that they provide 340B drugs to Medicaid patients.  And the fact is, HRSA has no existing legal authority to trump any such state requirement.  It will be important for 340B covered entities, and their contract pharmacies, to monitor changes to state laws and regulations governing the provision of 340B drugs to Medicaid beneficiaries, and the resulting requirements for billing and reimbursement of those drugs to the states.

©1994-2017 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

TRENDING LEGAL ANALYSIS


About this Author

Lauren Moldawer, healthcare, health, attorney, CMS, Mintz Levin, law firm
Associate

Lauren's practice focuses on advising health care providers, PBMs, and managed care organizations on a variety of regulatory issues.*

Prior to joining the firm, Lauren* worked at the Centers for Medicare & Medicaid Services (CMS) in the Medicare-Medicaid Coordination Office. In this role, she worked with states and health plans implementing the Financial Alignment Demonstration, which is a CMS initiative that seeks to better integrate Medicare and Medicaid services for dual-eligible individuals. Prior to her tenure with CMS, she was a...

202-434-7486
Ellyn Sternfield, Government Health Care Attorney, Mintz Levin, Law firm
Of Counsel

Ellyn has more than 30 years of legal experience, with an extensive background in the field of government health care enforcement.

Ellyn’s experience enables her to provide valuable insight to clients facing potential state or federal investigations, or who have general compliance concerns. Ellyn currently represents a variety of health care product and service providers in federal and state administrative, civil, and criminal matters around the country. She conducts internal reviews and investigations for clients concerned about potential compliance issues. Ellyn advises clients on proposed or existing health care business arrangements, especially those involving Medicaid, Medicare, and the 340B Drug Pricing Program. Ellyn drafts compliance plans to help insulate clients from future whistleblower claims or enforcement efforts. And Ellyn helps negotiate resolutions of matters brought under federal or state false claims acts. 

202-434-7445